Treatment with vedolizumab or ustekinumab in Crohn’s disease, or vedolizumab in ulcerative colitis, followed by an anti–tumor necrosis factor agent was found to be at least as safe as treatment with two successive anti-TNF agents in a retrospective analysis of a large clinical database.
As part of the ROTARY study, investigators led by Noa Krugliak-Cleveland, MD, an assistant professor in the Department of Medicine at the University of Chicago Medicine, assessed the frequency of